



**Chronic Pain in the Year of a Pandemic:
Advanced Practice Provider Edition**

Brett Snodgrass, FNP-C, ACHPN, CPE, FAANP

1

Disclosure

- Speakers Bureau: Salix Pharmaceuticals




2

Learning Objectives

- Describe the changes of chronic pain management during the pandemic
- Identify the specific points to include in a chronic pain visit
- Explain how telemedicine pertains to chronic pain and the pandemic



3



4

Including..... Chronic Pain

Hospitalizations were 6 times higher and deaths 12 times higher for COVID-19 patients with reported underlying conditions*


MOST FREQUENTLY REPORTED UNDERLYING CONDITIONS

- CARDIOVASCULAR DISEASE
- DIABETES
- CHRONIC LUNG DISEASE

*compared to those with no reported underlying health conditions

PainWeek CDC.GOV BY: @MMWR67020 **MMWR**

5



6

Considerations and Recommendations: COVID 19 International Consensus

PainWeek

7

Considerations and Recommendations

- **The Immune Response and Opioid Therapy**
 - Higher risk mortality in elderly
 - Hypertension, Diabetes, Coronary Artery Disease, COPD, cancer
 - Endocrine changes associated with opioid therapy
 - Immune response/inflammatory response
 - Immunosuppressive
 - Most - Morphine & Fentanyl
 - Least - Buprenorphine
 - Chronic pain patients on opioids - potentially more susceptible to COVID-19

PainWeek

8

Considerations and Recommendations

- **Steroids**
 - Potential for secondary adrenal insufficiency and altered immune response
 - Dexamethasone and betamethasone less immune suppression
 - In a large retrospective study, the injection of corticosteroids into joints was shown to be associated with a higher risk of influenza [
- **Psychological, Physical and Social Functions**
 - higher prevalence of anxiety, depression, catastrophising and suicidal ideation. This may worsen during a period of crisis.

PainWeek

9

Therapeutic Consideration and Recommendations

- Inpatient Visits
 - Any elective in-person patient visits or meetings should be suspended.
 - No elective pain procedures should be performed, except specific semi-urgent procedures.



10

Therapeutic Consideration and Recommendations

- Use of Telemedicine
 - First approach and exclusively in most cases.
 - Ensure adherence to the subscribed needs of telemedicine required by individual state



11

Therapeutic Consideration and Recommendations

- Biopsychosocial Management of Pain
 - Telemedicine platforms are available to engage in multidisciplinary interactions.
 - Online self-management programs that integrate components of exercise, sleep hygiene, pacing and healthy lifestyle should be considered.
 - Multidisciplinary therapies could be helpful in overcoming increased opioids needs and/or procedures during the pandemic



12

Therapeutic Consideration and Recommendations

▪ Prescribing Opioids

- Use telemedicine to evaluate, initiate and continue opioid prescriptions.
- Ensure all patients receive their appropriate prescription of opioids to avoid withdrawal.
- Naloxone education and prescription for high-risk patients.



13

Therapeutic Consideration and Recommendations

▪ Prescribing Opioids

- Inform patients of the risks and impact of long-term opioid therapy on the immune system.
- Communicate with other healthcare providers in the patients' circle-of-care including family HCPs, pharmacists and nurses



14

Therapeutic Consideration and Recommendations

▪ NSAID Recommendations

- All patients prescribed or who use non-steroidal anti-inflammatory drugs on a regular basis continue their use
 - monitoring for adverse effects.
- Educate patients on non-steroidal anti-inflammatory drugs that any mild fever or new myalgia should be promptly reported.



15

Therapeutic Consideration and Recommendations

- **Steroid Recommendations**
 - Increase potential for adrenal insufficiency and altered immune response.
 - Intraarticular steroid injections could increase the risk of viral infection.
 - Duration of immune suppression could be less with the use of dexamethasone and betamethasone.
 - Consider evaluating risks and benefits of steroid injections and use a decreased dose



16

Therapeutic Consideration and Recommendations

- **Intrathecal Recommendations**
 - Avoid insertion of any new intrathecal pump (ITP) except for highly selected cancer pain cases where the benefit is considered to outweigh the risk.
 - Consider proceeding straight to an implant, without a trial, for appropriate candidates.
 - In COVID-19 suspected or symptomatic patients, consider the possibility of delaying the refill if the low reservoir alarm date allows a time frame until the patient has served a recommended self-isolation period



17

Therapeutic Consideration and Recommendations

- **Neurostimulator Recommendations**
 - Avoid any new trials or implants.
 - Use telemedicine as much as possible to resolve patient concerns. An audiovisual interview makes it easier to evaluate or troubleshoot most issues




18

Therapeutic Consideration and Recommendations

- **Steroid Recommendations**
 - Increase potential for adrenal insufficiency and altered immune response.
 - Intraarticular steroid injections could increase the risk of viral infection.
 - Duration of immune suppression could be less with the use of dexamethasone and betamethasone.
 - Consider evaluating risks and benefits of steroid injections and use a decreased dose



19




20

Proper Documentation in Telemedicine for the Chronic Pain Patient



21



Painweek

22

Proper Documentation of Telehealth Video Visit

The above-named patient gives consent for this Telehealth visit and understands that "telehealth" is a video teleconferencing connection between the patient and the Healthcare provider. The patient understands the risks and benefits of a Telehealth visit, including that, 1) the Healthcare provider will do their best to provide reasonable medically necessary determination and treatment based on the client's Telehealth interview, history, and available test results, and 2) the limitation of Telehealth as not providing in-person live examination by the Healthcare provider.

Painweek

23

Tips for Telehealth

- Check and follow state laws pertaining to chronic pain and telehealth
- The primary condition of payment under telehealth is that the provider must conduct the patient visit using real-time, two-way communication that includes BOTH audio AND visual components.
- CPT Codes 99421-99423
- Consider live visits for urine drug screening or medical adherence

Painweek

24

Tips for Telehealth

- Live Visits
 - High Risk
 - Every 1-2 mos
 - Moderate Risk
 - Every 3-4 mos
 - Low Risk
 - Every 5-6 mos



25

Establish a Diagnosis.

Pain Is Not a Diagnosis....It's a Symptom

- Pain Management is not without liability
- Your liability greatly increases, if you treat a patient with controlled substances without a firm diagnosis



24

26

What Kind of Pain Is it?

- Neuropathic pain
 - Burning, electric
- Musculoskeletal pain
 - Localized pain, pain with movement
- Inflammatory pain
 - Visible inflammation



27

The 4 Pillars of Oral Pain Therapy

- 1) Anti-inflammatories
- 2) Anticonvulsants
- 3) Mood Modulators
 - SNRIs
 - SSRIs
- 4) Opiates

Painweek

28

When Opioids are Appropriate in Telemedicine

Painweek

29


The Pain Assessment


Painweek


30


Clinical Interview: Pain & Treatment History


Description of pain


Location


Intensity


Quality


Onset/Duration


Variations/Patterns/Rhythm

What relieves the pain?

What causes or increases pain?

Effects of pain on physical, emotional, and psychosocial function

Patient's pain & functional goals

PainWeek

31

Clinical Interview: Pain & Treatment History, cont'd

Pain Medications



Pain Medications

Past use

Current use

- Query state **PDMP** where available to confirm patient report
- Contact past providers & obtain prior medical records
- Conduct **UDT**

Dosage

- For opioids currently prescribed: opioid, dose, regimen, & duration
 - Important to determine if patient is **opioid tolerant**

General effectiveness

Nonpharmacologic strategies & effectiveness

PainWeek

32


Assess Risk of Abuse, Including Substance Use & Psychiatric Hx

Obtain a complete Hx of current & past substance use

- Prescription drugs
- Illegal substances
- Alcohol & tobacco
 - Substance abuse Hx does not prohibit treatment w/ ERLA opioids but may require additional monitoring & expert consultation/referral
- Family Hx of substance abuse & psychiatric disorders
- Hx of sexual abuse

Social history also relevant

Employment, cultural background, social network, marital history, legal history, & other behavioral patterns



PainWeek

33

Opioid Risk Tool - Revised (ORT-R)

The revised ORT has clinical usefulness in providing clinicians a simple, validated method to rapidly screen for the risk of developing OUD in patients on or being considered for opioid therapy.

Opioid Risk Tool – OUD (ORT-OUD)

This tool should be administered to patients upon an initial visit prior to beginning or continuing opioid therapy for pain management. A score of 2 or lower indicates low risk for future opioid use disorder; a score of >=3 indicates high risk for opioid use disorder.

Mark Each Box That Applies

	Yes	No
Family history of substance abuse		
Alcohol	1	0
Illegal drugs	1	0
Rx drugs	1	0
Personal history of substance abuse		
Alcohol	1	0
Illegal drugs	1	0
Rx drugs	1	0
Age between 18-45 years	1	0
Psychological disease		
ADHD, OCD, bipolar, schizophrenia	1	0
Depression	1	0
Scoring total		
	0	0

Chenille, M, Compton, P, Ortega, L, Weaver, T, O'Brien, C. (2018) Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Pain Management. *Pain: The Journal of Pain*. 019(11). Available online: <https://doi.org/10.1016/j.pain.2018.05.022>. Accessed June 28, 2019.

PainWeek

34

Reasons for Discontinuing Opioids

<p>No progress toward therapeutic goals</p> <p>Nonadherence or unsafe behavior</p> <ul style="list-style-type: none"> • 1 or 2 episodes of increasing dose without prescriber knowledge • Sharing medications • Unapproved opioid use to treat another symptom (e.g., insomnia) 	<p>Intolerable & Unmanageable AEs</p> <p>Aberrant behaviors suggestive of addiction &/or diversion</p> <ul style="list-style-type: none"> • Use of illicit drugs or unprescribed opioids • Repeatedly obtaining opioids from multiple outside sources • Prescription forgery • Multiple episodes of prescription loss 	<p>Pain level decreases in stable patients</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------

PainWeek

35

Utilize a PPA

Reinforce expectations for appropriate & safe opioid use

- Obtain opioids from a single prescriber
- Fill opioid prescriptions at a designated pharmacy
- Safeguard opioids
 - Do not store in medicine cabinet
 - Keep locked (e.g., use a medication safe)
 - Do not share or sell medication
- Instructions for disposal when no longer needed
- Commitments to return for follow-up visits
- Comply w/ appropriate monitoring
 - E.g., random UDT & pill counts
- Frequency of prescriptions
- Enumerate behaviors that may lead to opioid discontinuation
- An exit strategy

PainWeek

36

References

- Alonso-Matielo, H., da Silva Oliveira, V. R., de Oliveira, V. T., & Dale, C. S. (2021). Pain in Covid Era. *Frontiers in physiology*, 12, 624154. <https://doi.org/10.3389/fphys.2021.624154>
- de Moraes, É. B., Santos Garcia, J. B., de Macedo Antunes, J., Daher, D. V., Seixas, F. L., & Muniz Ferrari, M. F. (2021). Chronic Pain Management during the Covid-19 Pandemic: A Scoping Review. *Pain management nursing : official journal of the American Society of Pain Management Nurses*, 22(2), 103–110. <https://doi.org/10.1016/j.pmn.2020.11.010>
- Shanthanna, H., Strand, N. H., Provenzano, D. A., Lobo, C. A., Eldabe, S., Bhatia, A., Wegener, J., Curtis, K., Cohen, S. P., & Narouze, S. (2020). Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel. *Anaesthesia*, 75(7), 935–944. <https://doi.org/10.1111/anae.15076>